Excess mortality in patients with AIDS in the era of highly active antiretroviral therapy: temporal changes and risk factors.
BACKGROUND
Excess mortality has decreased among human immunodeficiency virus (HIV)-infected patients but without evidence of a decrease among patients with AIDS. We assessed temporal changes in excess mortality and elucidated risk factors for excess mortality in patients with AIDS diagnosed in the era of highly active antiretroviral therapy (HAART).


METHODS
We included 1188 patients of the Longitudinal Study of Ocular Complications in AIDS who were aged 25-64 years at enrollment and who received a diagnosis of AIDS after 1995. We calculated excess mortality as the age-, year-, and sex-adjusted difference in mortality rates between patients with AIDS and persons in the US general population during the period 1999-2007. We used a relative survival model to identify risk factors for excess mortality.


RESULTS
There were a mean of 50 excess deaths per 1000 person-years (95% confidence interval [CI], 44-57 excess deaths per 1000 person-years) during 1999-2007. Excess mortality almost halved, with an annual decrease of 8.0% per year (95% CI, 3.0%-12.7%; P = .002) but remained high at 36 excess deaths per 1000 person-years in 2007. Viral load >400 copies/mL (compared with <or= 400 copies/mL; risk ratio, 3.4; 95% CI, 2.3-5.0), CD4(+) count <200 cells/μL (compared with >or= 200 cells/μL; risk ratio, 2.7; 95% CI, 1.9-3.9), and cytomegalovirus retinitis (risk ratio, 1.6; 95% CI, 1.2-2.1) were the strongest risk factors for excess mortality.


CONCLUSIONS
Excess mortality among patients with AIDS was nearly halved in the HAART era and most strongly linked to stage of HIV disease. These results reflect the continuing improvements in AIDS management but also highlight that excess mortality remains ∼5 times higher in patients with AIDS than in HIV-infected patients without AIDS.
Puhan
Milo A
MA
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, USA. mpuhan@jhsph.edu
Van Natta
Mark L
ML
Palella
Frank J
FJ
Addessi
Adrienne
A
Meinert
Curtis
C
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000401:mortality*; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D016019:Survival Analysis; D013997:Time Factors; D014481:United States / Q000453:epidemiology
D019380:Anti-HIV Agents
N Engl J Med. 2009 Apr 30;360(18):1815-26
19339714
AIDS. 2003 May 23;17(8):1179-93
12819520
N Engl J Med. 1998 Mar 26;338(13):853-60
9516219
Stat Med. 2004 Jan 15;23(1):51-64
14695639
Epidemiology. 2004 Sep;15(5):536-42
15308952
Ann Intern Med. 2007 Jan 16;146(2):87-95
17227932
AIDS. 2008 Jan 2;22(1):89-95
18090396
Lancet. 2003 Sep 13;362(9387):877-8
13678976
Ophthalmology. 2007 Apr;114(4):787-93
17210182
Ann Intern Med. 2003 Apr 15;138(8):620-6
12693883
J Clin Epidemiol. 2003 Dec;56(12):1185-91
14680669
MMWR Morb Mortal Wkly Rep. 2008 Oct 3;57(39):1073-6
18830210
MMWR Morb Mortal Wkly Rep. 2009 Jun 26;58(24):661-5
19553901
Lancet. 2002 Jul 13;360(9327):119-29
12126821
Ophthalmology. 2007 Apr;114(4):780-6
17258320
J Acquir Immune Defic Syndr. 2006 Sep;43(1):27-34
16878047
JAMA. 2008 Jul 2;300(1):51-9
18594040